Global Brain has invested in Switch Therapeutics, Inc., a biotech pioneering a new class of RNA medicine

Global Brain has invested in Switch Therapeutics, Inc. (Switch), a biotech developing a cell-selective gene knockdown platform, through its GB-VIII Growth Fund Investment Limited Partnership (GB-VIII).

Switch is a preclinical-stage biotechnology company pioneering a new type of RNA medicine. As its name suggests, their proprietary technology, Conditionally Activated siRNAs (CASi) platform, allows for cell-selective gene knockdown, as well as efficient self-delivery and uptake, potency, and duration of knockdown. The biotech originates from the work of the leading scientists at Caltech, Harvard Medical School, and City of Hope. Switch will start in the central nervous system and may strategically expand into other disease areas with potential pharma partners.

Global Brain has decided to invest in Switch, highly recognizing its transformational RNA science and the experienced team with a proven track record. Global Brain will contribute to the growth of Switch, leveraging the network in the pharmaceutical and other industries worldwide.